Read more
3:51 PM · 27 October 2020

Eli Lilly shares slump after earnings report

Eli Lilly
Stocks
LLY.US, Eli Lilly & Co
-
-
Eli Lilly (LLY.US) shares fell over 5.5 % after the company posted weaker than expected quarterly figures. Drugmaker earned $1.54 per share while analysts' expected earnings of $1.71 per share.  Revenue rose 5% to $5.741 billion from $5.477 billion in the previous quarter, but also came in below estimates of $5.875 billion due to the poor sales of its diabetes drugs. Also CEO David Ricks also pointed out to CNBC that investments in Covid-19 treatments that were not in its prior guidance also hurt results.
Separately, an independent committee  recommended the end of clinical trials of Eli Lilly’s Covid-19 antibody drug bamlanivimab in combination with Gilead Sciences (GILD.US ) antiviral treatment remdesivir as it did not show a benefit.
Eli Lilly (LLY.US) stock tumbled to a nearly seven-month low during today's session. Currently price is testing local support at $133.00. If the current sentiment prevails, the downward move could be extended to the $122.40 handle. However, should bulls regain control, then resistance at $140.00 could be at risk. Source: xStation5
5 December 2025, 3:30 PM

Netflix buys up Warner Bros - What does it mean for streaming and markets?

5 December 2025, 3:11 PM

US Open: US indices gain after PCE data 🗽Semiconductor stocks surge

5 December 2025, 11:42 AM

DE40: Adequate data, Mild growth

5 December 2025, 9:04 AM

Chart of the day: CHN.cash (05.12.2025)

Join over 2 000 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits